Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special ...

Recursion (RXRX) soars on receiving an investment worth $50 million from Nivida for drug development using artificial intelligence.

Nvidia’s investment isn’t just working capital for Recursion Pharmaceuticals’ technology-driven drug discovery research. Recursion says it will get more computing power as well as the ...

Recursion’s pipeline shuffle follows the company’s acquisition of AI development peer Exscientia late last year.

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. The deal de-risks the company's pipeline by removing uncertainty; however, there's still a long way to go before REV102 ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on ...

Official support for free-threaded Python, an experimental JIT, and a smarter installation manager for Windows are among the goodies in Python 3.14. Now in a release candidate.